Abuse Potential of Pregabalin: A Systematic Review

CNS Drugs

Volumn 30, Issue 1, 2016, Pages 9-25

  Schjerning, Ole ^a,b,f   Rosenzweig, Mary ^c   Pottegård, Anton ^d   Damkier, Per ^d,e   Nielsen, Jimmi ^a,b  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

^c Danish Health and Medicines Authority   (Denmark)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f Centre for Schizophrenia   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; GABAPENTIN; GLUTAMIC ACID; PREGABALIN; STREET DRUG;

BIBLIOGRAPHIC DATABASE; CLINICAL DECISION MAKING; DRUG ABUSE; DRUG DISCRIMINATION; DRUG POTENCY; DRUG UTILIZATION; HUMAN; MEDICAL HISTORY; META ANALYSIS; PLACE PREFERENCE; PRIORITY JOURNAL; REVIEW; SUBSTANCE ABUSE; SYSTEMATIC REVIEW; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; DRUG MISUSE; EUPHORIA; PRECLINICAL STUDY; STATISTICS AND NUMERICAL DATA; SUBSTANCE-RELATED DISORDERS;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; EUPHORIA; HUMANS; PREGABALIN; PRESCRIPTION DRUG MISUSE; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 84956591825     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-015-0303-6     Document Type: Review

References (82)

1. Montgomery S, Emir B, Haswell H, Prieto R. Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability. Curr Med Res Opin. 2013;29:1223-30.
2. de Guglielmo G, Cippitelli A, Somaini L, Gerra G, Li H, Stopponi S, et al. Pregabalin reduces cocaine self-administration and relapse to cocaine seeking in the rat. Addict Biol. 2013;18:644-53.
3. Medstat.dk-National Institute for Health Data and Disease Control. Usage data on Lyrica. 2014. http://medstat.dk/en. Accessed 29 Nov 2014.
4. Pharma Marketing. Top 50 pharmaceutical products by global sales. 2015. http://www.pmlive.com/top-pharma-list/Top-50-pharmaceutical-products-by-global-sales. Accessed 28 Oct 2015.
5. Wettermark B, Brandt L, Kieler H, Boden R. Pregabalin is increasingly prescribed for neuropathic pain, generalised anxiety disorder and epilepsy but many patients discontinue treatment. Int J Clin Pract. 2014;68:104-10.
6. Cho YW, Song ML. Effects of pregabalin in patients with hypnotic-dependent insomnia. J Clin Sleep Med. 2014;10:545-50.
7. Oulis P, Kalogerakou S, Anyfandi E, Konstantakopoulos G, Papakosta VM, Masdrakis V, et al. Cognitive effects of pregabalin in the treatment of long-term benzodiazepine-use and dependence. Hum Psychopharmacol. 2014;29:224-9.
8. Guglielmo R, Martinotti G, Clerici M, Janiri L. Pregabalin for alcohol dependence: a critical review of the literature. Adv Ther. 2012;29:947-57.
9. Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2011;52:826-36.
10. Halaby A, Kassm SA, Naja WJ. Pregabalin dependence: a case report. Curr Drug Saf. 2015;10:184-6.
11. Grosshans M, Lemenager T, Vollmert C, Kaemmerer N, Schreiner R, Mutschler J, et al. Pregabalin abuse among opiate addicted patients. Eur J Clin Pharmacol. 2013;69:2021-5.
12. European Medicine Agency. Summary of product characteristics for pregabalin. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/003880/WC500166172.pdf. Accessed 29 Nov 2014.
13. Expert P. Abuse liability assessment of CNS drugs: conclusions, recommendations, and research priorities. Drug Alcohol Depend. 2003;70(3 Suppl.):S107-14.
14. Balster RL, Bigelow GE. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend. 2003;70:S13-40.
15. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
16. Smith SM, Dart RC, Katz NP, Paillard F, Adams EH, Comer SD, et al. Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain. 2013;154:2287-96.
17. Center for Drug Evaluation and Research US. Consult on abuse potential for NDA review, Lyrica (Pregabalin). In: FaDAP, editor. Review. USA: US Food and Drug Administration; 2004.
18. Andrews N, Loomis S, Blake R, Ferrigan L, Singh L, McKnight AT. Effect of gabapentin-like compounds on development and maintenance of morphine-induced conditioned place preference. Psychopharmacology (Berl). 2001;157:381-7.
19. Rutten K, De Vry J, Robens A, Tzschentke TM, van der Kam EL. Dissociation of rewarding, anti-aversive and anti-nociceptive effects of different classes of anti-nociceptives in the rat. Eur J Pain. 2011;15:299-305.
20. Stopponi S, Somaini L, Cippitelli A, de Guglielmo G, Kallupi M, Cannella N, et al. Pregabalin reduces alcohol drinking and relapse to alcohol seeking in the rat. Psychopharmacology (Berl). 2012;220:87-96.
21. Becker HC, Myrick H, Veatch LM. Pregabalin is effective against behavioral and electrographic seizures during alcohol withdrawal. Alcohol Alcohol. 2006;41:399-406.
22. Aracil-Fernandez A, Almela P, Manzanares J. Pregabalin and topiramate regulate behavioural and brain gene transcription changes induced by spontaneous cannabinoid withdrawal in mice. Addict Biol. 2013;18:252-62.
23. Hasanein P, Shakeri S. Pregabalin role in inhibition of morphine analgesic tolerance and physical dependency in rats. Eur J Pharmacol. 2014;742:113-7.
24. Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP Jr, Sharma U, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;9:792-805.
25. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264-73.
26. Ohta H, Oka H, Usui C, Ohkura M, Suzuki M, Nishioka K. A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia. Arthritis Res Ther. 2012;14:R217.
27. Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP Jr, Martin SA, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008;35:502-14.
28. Nasser K, Kivitz AJ, Maricic MJ, Silver DS, Silverman SL. Twice daily versus once nightly dosing of pregabalin for fibromyalgia: a double-blind randomized clinical trial of efficacy and safety. Arthritis Care Res (Hoboken). 2014;66:293-300.
29. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63:2104-10.
30. Atalay H, Solak Y, Biyik Z, Gaipov A, Guney F, Turk S. Cross-over, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in haemodialysis patients. Clin Drug Investig. 2013;33:401-8.
31. Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol. 2008;8:33.
32. Stacey BR, Barrett JA, Whalen E, Phillips KF, Rowbotham MC. Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief. J Pain. 2008;9:1006-17.
33. Simpson DM, Schifitto G, Clifford DB, Murphy TK, Durso-De Cruz E, Glue P, et al. Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Neurology. 2010;74:413-20.
34. Gilron I, Wajsbrot D, Therrien F, Lemay J. Pregabalin for peripheral neuropathic pain: a multicenter, enriched enrollment randomized withdrawal placebo-controlled trial. Clin J Pain. 2011;27:185-93.
35. Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry. 2003;160:533-40.
36. Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol. 2005;25:151-8.
37. Allen R, Chen C, Soaita A, Wohlberg C, Knapp L, Peterson BT, et al. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med. 2010;11:512-9.
38. Olesen SS, Bouwense SA, Wilder-Smith OH, van Goor H, Drewes AM. Pregabalin reduces pain in patients with chronic pancreatitis in a randomized, controlled trial. Gastroenterology. 2011;141:536-43.
39. Chew ML, Alvey CW, Plotka A, Pitman VW, Alebic-Kolbah T, Scavone JM, et al. Pregabalin controlled-release pharmacokinetics in healthy volunteers: analysis of four multiple-dose randomized clinical pharmacology studies. Clin Drug Investig. 2014;34:627-37.
40. Lang N, Sueske E, Hasan A, Paulus W, Tergau F. Pregabalin exerts oppositional effects on different inhibitory circuits in human motor cortex: a double-blind, placebo-controlled transcranial magnetic stimulation study. Epilepsia. 2006;47:813-9.
41. Chua YC, Ng KS, Sharma A, Jafari J, Surguy S, Yazaki E, et al. Randomised clinical trial: pregabalin attenuates the development of acid-induced oesophageal hypersensitivity in healthy volunteers - a placebo-controlled study. Aliment Pharmacol Ther. 2012;35:319-26.
42. Chew ML, Plotka A, Alvey CW, Pitman VW, Alebic-Kolbah T, Scavone JM, et al. Pharmacokinetics of pregabalin controlled-release in healthy volunteers: effect of food in five single-dose, randomized, clinical pharmacology studies. Clin Drug Investig. 2014;34:617-26.
43. Filipetto FA, Zipp CP, Coren JS. Potential for pregabalin abuse or diversion after past drug-seeking behavior. J Am Osteopath Assoc. 2010;110:605-7.
44. Grosshans M, Mutschler J, Hermann D, Klein O, Dressing H, Kiefer F, et al. Pregabalin abuse, dependence, and withdrawal: a case report. Am J Psychiatry. 2010;167:869.
45. Westin AA, Strom EJ. Yes, pregabalin can be abused! Tidsskr Nor Laegeforen. 2010;130:2108.
46. Yargic I, Ozdemiroglu FA. Pregabalin abuse: a case report/Pregabalin kötüye kullanlml: Bir olgu sunumu. Bull Clin Psychopharmacol. 2011;21:64-6.
47. Skopp G, Zimmer G. Pregabalin - a drug with abuse potential? Arch Kriminol. 2012;229:44-54.
48. Carrus D, Schifano F. Pregabalin misuse-related issues; intake of large dosages, drug-smoking allegations, and possible association with myositis: two case reports. J Clin Psychopharmacol. 2012;32:839-40.
49. Papazisis G, Garyfallos G, Sardeli C, Kouvelas D. Pregabalin abuse after past substance-seeking behavior. Int J Clin Pharmacol Ther. 2013;51:441-2.
50. Gahr M, Franke B, Freudenmann RW, Kolle MA, Schonfeldt-Lecuona C. Concerns about pregabalin: further experience with its potential of causing addictive behaviors. J Addict Med. 2013;7:147-9.
51. Landmark CJ, Fossmark H, Larsson PG, Rytter E, Johannessen SI. The prescription registry and abuse of pregabalin. Tidsskr Nor Laegeforen. 2011;131:223.
52. Boden R, Wettermark B, Brandt L, Kieler H. Factors associated with pregabalin dispensing at higher than the approved maximum dose. Eur J Clin Pharmacol. 2014;70:197-204.
53. Kapil V, Green JL, Le Lait M-C, Wood DM, Dargan PI. Misuse of the γ-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK. Br J Clin Pharmacol. 2014;78:190-1.
54. Schwan S, Sundstrom A, Stjernberg E, Hallberg E, Hallberg P. A signal for an abuse liability for pregabalin-results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol. 2010;66:947-53.
55. Gahr M, Freudenmann RW, Hiemke C, Kolle MA, Schonfeldt-Lecuona C. Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol. 2013;69:1335-42.
56. Wills B, Reynolds P, Chu E, Murphy C, Cumpston K, Stromberg P, et al. Clinical outcomes in newer anticonvulsant overdose: a poison center observational study. J Med Toxicol. 2014;10:254-60.
57. Baird CR, Fox P, Colvin LA. Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers. Eur Addict Res. 2014;20:115-8.
58. Jonsson B, Backman E, Salmonson H, Hojer J. Injection of crushed tablets-a prospective observational study. Clin Toxicol (Phila). 2014;52:982-3.
59. Kriikku P, Wilhelm L, Rintatalo J, Hurme J, Kramer J, Ojanpera I. Pregabalin serum levels in apprehended drivers. Forensic Sci Int. 2014;243:112-6.
60. Wilens T, Zulauf C, Ryland D, Carrellas N, Catalina-Wellington I. Prescription medication misuse among opioid dependent patients seeking inpatient detoxification. Am J Addict. 2014;24:173-7.
61. Hakkinen M, Vuori E, Kalso E, Gergov M, Ojanpera I. Profiles of pregabalin and gabapentin abuse by postmortem toxicology. Forensic Sci Int. 2014;241:1-6.
62. Launiainen T, Broms U, Keskitalo-Vuokko K, Pitkaniemi J, Pelander A, Kaprio J, et al. Nicotine, alcohol, and drug findings in young adults in a population-based postmortem database. Nicotine Tob Res. 2011;13:763-71.
63. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73:137-50.
64. Filip M, Frankowska M, Sadakierska-Chudy A, Suder A, Szumiec L, Mierzejewski P, et al. GABAB receptors as a therapeutic strategy in substance use disorders: focus on positive allosteric modulators. Neuropharmacology. 2015;88:36-47.
65. Vlachou S, Markou A. GABAB receptors in reward processes. Adv Pharmacol. 2010;58:315-71.
66. Tan KR, Brown M, Labouebe G, Yvon C, Creton C, Fritschy JM, et al. Neural bases for addictive properties of benzodiazepines. Nature. 2010;463:769-74.
67. Errante LD, Petroff OA. Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure. 2003;12:300-6.
68. Navarrete F, Perez-Ortiz JM, Manzanares J. Pregabalin- and topiramate-mediated regulation of cognitive and motor impulsivity in DBA/2 mice. Br J Pharmacol. 2012;167:183-95.
69. European Medicine Agency (EMA). Scientific discussion - Lyrica. In: Agency EM, editor. European Medicines Agency. 2005. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion-Variation/human/000546/WC500046605.pdf. Accessed 28 Nov 2015.
70. Arnold LM, Arsenault P, Huffman C, Patrick JL, Messig M, Chew ML, et al. Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo-controlled study. Curr Med Res Opin. 2014;30:2069-83.
71. Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49:661-9.
72. Bockbrader HN, Radulovic LL, Posvar EL, Strand JC, Alvey CW, Busch JA, et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol. 2010;50:941-50.
73. Pande AC, Feltner DE, Jefferson JW, Davidson JR, Pollack M, Stein MB, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol. 2004;24:141-9.
74. Sugandiran NBJ. Pregabalin may cause dependence even if it is not abused. Arc Cas Rep CMed. 2014;1:1.
75. Chalabianloo F, Schjott J. Pregabalin and its potential for abuse. Tidsskr Nor Laegeforen. 2009;129:186-7.
76. Hallas J, Nissen A. Individualized drug utilization statistics. Analysing a population's drug use from the perspective of individual users. Eur J Clin Pharmacol. 1994;47:367-72.
77. Hallas J, Stovring H. Templates for analysis of individual-level prescription data. Basic Clin Pharmacol Toxicol. 2006;98:260-5.
78. Schifano F, D'Offizi S, Piccione M, Corazza O, Deluca P, Davey Z, et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom. 2011;80:118-22.
79. Bramness JG. Abuse of pregabalin. Tidsskr Nor Laegeforen. 2010;130:1703-4.
80. Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs. 2014;28:491-6.
81. Papazisis G, Tzachanis D. Pregabalin's abuse potential: a mini review focusing on the pharmacological profile. Int J Clin Pharmacol Ther. 2014;52:709-16.
82. Baastrup C, Jensen TS, Finnerup NB. Pregabalin attenuates place escape/avoidance behavior in a rat model of spinal cord injury. Brain Res. 2011;1370:129-35.